Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 230

1.

The Immune Landscape of Cancer.

Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Ou Yang TH, Porta-Pardo E, Gao GF, Plaisier CL, Eddy JA, Ziv E, Culhane AC, Paull EO, Sivakumar IKA, Gentles AJ, Malhotra R, Farshidfar F, Colaprico A, Parker JS, Mose LE, Vo NS, Liu J, Liu Y, Rader J, Dhankani V, Reynolds SM, Bowlby R, Califano A, Cherniack AD, Anastassiou D, Bedognetti D, Rao A, Chen K, Krasnitz A, Hu H, Malta TM, Noushmehr H, Pedamallu CS, Bullman S, Ojesina AI, Lamb A, Zhou W, Shen H, Choueiri TK, Weinstein JN, Guinney J, Saltz J, Holt RA, Rabkin CE; Cancer Genome Atlas Research Network, Lazar AJ, Serody JS, Demicco EG, Disis ML, Vincent BG, Shmulevich L.

Immunity. 2018 Apr 17;48(4):812-830.e14. doi: 10.1016/j.immuni.2018.03.023. Epub 2018 Apr 5.

2.

JAMA Oncology-The Year in Review, 2017.

Disis MLN.

JAMA Oncol. 2018 May 1;4(5):632-633. doi: 10.1001/jamaoncol.2017.5108. No abstract available.

PMID:
29522127
3.

TLR8 ligation induces apoptosis of monocytic myeloid-derived suppressor cells.

Dang Y, Rutnam ZJ, Dietsch G, Lu H, Yang Y, Hershberg R, Disis ML.

J Leukoc Biol. 2018 Jan;103(1):157-164. doi: 10.1002/JLB.5AB0217-070R. Epub 2017 Dec 14.

PMID:
29345064
4.

Movie Review of The Immortal Life of Henrietta Lacks.

Disis MLN.

JAMA. 2017 Dec 26;318(24):2410-2412. doi: 10.1001/jama.2017.17916. No abstract available.

PMID:
29279906
5.

A First-in-Human Phase I Study of Subcutaneous Outpatient Recombinant Human IL15 (rhIL15) in Adults with Advanced Solid Tumors.

Miller JS, Morishima C, McNeel DG, Patel MR, Kohrt HEK, Thompson JA, Sondel PM, Wakelee HA, Disis ML, Kaiser JC, Cheever MA, Streicher H, Creekmore SP, Waldmann TA, Conlon KC.

Clin Cancer Res. 2018 Apr 1;24(7):1525-1535. doi: 10.1158/1078-0432.CCR-17-2451. Epub 2017 Dec 4.

PMID:
29203590
6.

Death by Gun Violence-A Public Health Crisis.

Bauchner H, Rivara FP, Bonow RO, Bressler NM, Disis MLN, Heckers S, Josephson SA, Kibbe MR, Piccirillo JF, Redberg RF, Rhee JS, Robinson JK.

JAMA Psychiatry. 2017 Dec 1;74(12):1195-1196. doi: 10.1001/jamapsychiatry.2017.3616. No abstract available.

PMID:
29052736
7.

Death by Gun Violence-A Public Health Crisis.

Bauchner H, Rivara FP, Bonow RO, Bressler NM, Disis MLN, Heckers S, Josephson SA, Kibbe MR, Piccirillo JF, Redberg RF, Rhee JS, Robinson JK.

JAMA Facial Plast Surg. 2018 Jan 1;20(1):7-8. doi: 10.1001/jamafacial.2017.1944. No abstract available.

PMID:
29052735
8.

Death by Gun Violence-A Public Health Crisis.

Bauchner H, Rivara FP, Bonow RO, Bressler NM, Disis MLN, Heckers S, Josephson SA, Kibbe MR, Piccirillo JF, Redberg RF, Rhee JS, Robinson JK.

JAMA Intern Med. 2017 Dec 1;177(12):1724-1725. doi: 10.1001/jamainternmed.2017.6917. No abstract available.

PMID:
29052733
9.

Death by Gun Violence-A Public Health Crisis.

Bauchner H, Rivara FP, Bonow RO, Bressler NM, Disis MLN, Heckers S, Josephson SA, Kibbe MR, Piccirillo JF, Redberg RF, Rhee JS, Robinson JK.

JAMA Cardiol. 2017 Dec 1;2(12):1301-1302. doi: 10.1001/jamacardio.2017.4413. No abstract available.

PMID:
29052725
10.

Death by Gun Violence-A Public Health Crisis.

Bauchner H, Rivara FP, Bonow RO, Bressler NM, Disis MLN, Heckers S, Josephson SA, Kibbe MR, Piccirillo JF, Redberg RF, Rhee JS, Robinson JK.

JAMA Pediatr. 2017 Dec 1;171(12):1142-1143. doi: 10.1001/jamapediatrics.2017.4359. No abstract available.

PMID:
29052724
11.

Death by Gun Violence-A Public Health Crisis.

Bauchner H, Rivara FP, Bonow RO, Bressler NM, Disis MLN, Heckers S, Josephson SA, Kibbe MR, Piccirillo JF, Redberg RF, Rhee JS, Robinson JK.

JAMA Neurol. 2017 Dec 1;74(12):1402-1403. doi: 10.1001/jamaneurol.2017.3533. No abstract available.

PMID:
29052723
12.

Death by Gun Violence-A Public Health Crisis.

Bauchner H, Rivara FP, Bonow RO, Bressler NM, Disis MLN, Heckers S, Josephson SA, Kibbe MR, Piccirillo JF, Redberg RF, Rhee JS, Robinson JK.

JAMA Ophthalmol. 2017 Dec 1;135(12):1293-1294. doi: 10.1001/jamaophthalmol.2017.5180. No abstract available.

PMID:
29052722
13.

Death by Gun Violence-A Public Health Crisis.

Bauchner H, Rivara FP, Bonow RO, Bressler NM, Disis MLN, Heckers S, Josephson SA, Kibbe MR, Piccirillo JF, Redberg RF, Rhee JS, Robinson JK.

JAMA. 2017 Nov 14;318(18):1763-1764. doi: 10.1001/jama.2017.16446. No abstract available.

PMID:
29052721
14.

Death by Gun Violence-A Public Health Crisis.

Bauchner H, Rivara FP, Bonow RO, Bressler NM, Disis ML, Heckers S, Josephson SA, Kibbe MR, Piccirillo JF, Redberg RF, Rhee JS, Robinson JK.

JAMA Oncol. 2017 Dec 1;3(12):1630-1631. doi: 10.1001/jamaoncol.2017.4357. No abstract available.

PMID:
29052720
15.

Death by Gun Violence-A Public Health Crisis.

Bauchner H, Rivara FP, Bonow RO, Bressler NM, Disis MLN, Heckers S, Josephson SA, Kibbe MR, Piccirillo JF, Redberg RF, Rhee JS, Robinson JK.

JAMA Surg. 2017 Dec 1;152(12):1103-1104. doi: 10.1001/jamasurg.2017.4797. No abstract available.

PMID:
29052719
16.

Death by Gun Violence-A Public Health Crisis.

Bauchner H, Rivara FP, Bonow RO, Bressler NM, Disis MLN, Heckers S, Josephson SA, Kibbe MR, Piccirillo JF, Redberg RF, Rhee JS, Robinson JK.

JAMA Otolaryngol Head Neck Surg. 2017 Oct 9. doi: 10.1001/jamaoto.2017.2577. [Epub ahead of print] No abstract available.

PMID:
29052718
17.

Death by Gun Violence-A Public Health Crisis.

Bauchner H, Rivara FP, Bonow RO, Bressler NM, Disis MLN, Heckers S, Josephson SA, Kibbe MR, Piccirillo JF, Redberg RF, Rhee JS, Robinson JK.

JAMA Dermatol. 2017 Dec 1;153(12):1223-1224. doi: 10.1001/jamadermatol.2017.4972. No abstract available.

PMID:
29052717
18.

Scholarly productivity and professional advancement of junior researchers receiving KL2, K23, or K08 awards at a large public research institution.

Amory JK, Louden DKN, McKinney C, Rich J, Long-Genovese S, Disis ML.

J Clin Transl Sci. 2017 Apr;1(2):140-143. doi: 10.1017/cts.2016.22. Epub 2017 Apr 19.

19.

Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy.

Gnjatic S, Bronte V, Brunet LR, Butler MO, Disis ML, Galon J, Hakansson LG, Hanks BA, Karanikas V, Khleif SN, Kirkwood JM, Miller LD, Schendel DJ, Tanneau I, Wigginton JM, Butterfield LH.

J Immunother Cancer. 2017 May 16;5:44. doi: 10.1186/s40425-017-0243-4. eCollection 2017. Review.

20.

Next generation approaches for tumor vaccination.

Patel A, Kaufman HL, Disis ML.

Chin Clin Oncol. 2017 Apr;6(2):19. doi: 10.21037/cco.2017.02.04. Review.

21.

Precancer Atlas to Drive Precision Prevention Trials.

Spira A, Yurgelun MB, Alexandrov L, Rao A, Bejar R, Polyak K, Giannakis M, Shilatifard A, Finn OJ, Dhodapkar M, Kay NE, Braggio E, Vilar E, Mazzilli SA, Rebbeck TR, Garber JE, Velculescu VE, Disis ML, Wallace DC, Lippman SM.

Cancer Res. 2017 Apr 1;77(7):1510-1541. doi: 10.1158/0008-5472.CAN-16-2346.

22.

Gene expression markers of Tumor Infiltrating Leukocytes.

Danaher P, Warren S, Dennis L, D'Amico L, White A, Disis ML, Geller MA, Odunsi K, Beechem J, Fling SP.

J Immunother Cancer. 2017 Feb 21;5:18. doi: 10.1186/s40425-017-0215-8. eCollection 2017.

23.

JAMA Oncology-The Year in Review, 2016.

Disis MLN.

JAMA Oncol. 2017 Apr 1;3(4):450-451. doi: 10.1001/jamaoncol.2016.7045. No abstract available.

PMID:
28196194
24.

Immunotherapy in breast cancer: An introduction.

Disis ML, Stanton SE.

Breast. 2018 Feb;37:196-199. doi: 10.1016/j.breast.2017.01.013. Epub 2017 Feb 3.

PMID:
28162837
25.

Topical Imiquimod Plus Nab-paclitaxel for Breast Cancer Cutaneous Metastases: A Phase 2 Clinical Trial.

Salazar LG, Lu H, Reichow JL, Childs JS, Coveler AL, Higgins DM, Waisman J, Allison KH, Dang Y, Disis ML.

JAMA Oncol. 2017 Jul 1;3(7):969-973. doi: 10.1001/jamaoncol.2016.6007.

26.

Phase II trial of albumin-bound paclitaxel and granulocyte macrophage colony-stimulating factor as an immune modulator in recurrent platinum resistant ovarian cancer.

Liao JB, Swensen RE, Ovenell KJ, Hitchcock-Bernhardt KM, Reichow JL, Apodaca MC, D'Amico L, Childs JS, Higgins DM, Buening BJ, Goff BA, Disis ML.

Gynecol Oncol. 2017 Mar;144(3):480-485. doi: 10.1016/j.ygyno.2017.01.008. Epub 2017 Jan 12.

PMID:
28089377
27.

Immunization against HIF-1α Inhibits the Growth of Basal Mammary Tumors and Targets Mammary Stem Cells In Vivo.

Cecil DL, Slota M, O'Meara MM, Curtis BC, Gad E, Dang Y, Herendeen D, Rastetter L, Disis ML.

Clin Cancer Res. 2017 Jul 1;23(13):3396-3404. doi: 10.1158/1078-0432.CCR-16-1678. Epub 2016 Dec 30.

28.

Selection of epitopes from self-antigens for eliciting Th2 or Th1 activity in the treatment of autoimmune disease or cancer.

Watt WC, Cecil DL, Disis ML.

Semin Immunopathol. 2017 Apr;39(3):245-253. doi: 10.1007/s00281-016-0596-7. Epub 2016 Dec 14. Review.

PMID:
27975138
29.

Surrogate in vitro activation of innate immunity synergizes with interleukin-7 to unleash rapid antigen-driven outgrowth of CD4+ and CD8+ human peripheral blood T-cells naturally recognizing MUC1, HER2/neu and other tumor-associated antigens.

Pathangey LB, McCurry DB, Gendler SJ, Dominguez AL, Gorman JE, Pathangey G, Mihalik LA, Dang Y, Disis ML, Cohen PA.

Oncotarget. 2017 Feb 14;8(7):10785-10808. doi: 10.18632/oncotarget.13911.

30.

Immunotherapy of head and neck cancer: Emerging clinical trials from a National Cancer Institute Head and Neck Cancer Steering Committee Planning Meeting.

Bauman JE, Cohen E, Ferris RL, Adelstein DJ, Brizel DM, Ridge JA, O'Sullivan B, Burtness BA, Butterfield LH, Carson WE, Disis ML, Fox BA, Gajewski TF, Gillison ML, Hodge JW, Le QT, Raben D, Strome SE, Lynn J, Malik S.

Cancer. 2017 Apr 1;123(7):1259-1271. doi: 10.1002/cncr.30449. Epub 2016 Dec 1.

31.

Phase Ib Trial of the Toll-like Receptor 8 Agonist, Motolimod (VTX-2337), Combined with Cetuximab in Patients with Recurrent or Metastatic SCCHN.

Chow LQM, Morishima C, Eaton KD, Baik CS, Goulart BH, Anderson LN, Manjarrez KL, Dietsch GN, Bryan JK, Hershberg RM, Disis ML, Martins RG.

Clin Cancer Res. 2017 May 15;23(10):2442-2450. doi: 10.1158/1078-0432.CCR-16-1934. Epub 2016 Nov 3.

32.

Clinical significance of tumor-infiltrating lymphocytes in breast cancer.

Stanton SE, Disis ML.

J Immunother Cancer. 2016 Oct 18;4:59. eCollection 2016. Review.

33.

Leveraging premalignant biology for immune-based cancer prevention.

Spira A, Disis ML, Schiller JT, Vilar E, Rebbeck TR, Bejar R, Ideker T, Arts J, Yurgelun MB, Mesirov JP, Rao A, Garber J, Jaffee EM, Lippman SM.

Proc Natl Acad Sci U S A. 2016 Sep 27;113(39):10750-8. doi: 10.1073/pnas.1608077113. Epub 2016 Sep 16.

34.

Variation in the Incidence and Magnitude of Tumor-Infiltrating Lymphocytes in Breast Cancer Subtypes: A Systematic Review.

Stanton SE, Adams S, Disis ML.

JAMA Oncol. 2016 Oct 1;2(10):1354-1360. doi: 10.1001/jamaoncol.2016.1061. Review.

PMID:
27355489
35.

Concurrent SPECT/PET-CT imaging as a method for tracking adoptively transferred T-cells in vivo.

Stanton SE, Eary JF, Marzbani EA, Mankoff D, Salazar LG, Higgins D, Childs J, Reichow J, Dang Y, Disis ML.

J Immunother Cancer. 2016 May 17;4:27. doi: 10.1186/s40425-016-0131-3. eCollection 2016.

36.

The Human Vaccines Project: A roadmap for cancer vaccine development.

Romero P, Banchereau J, Bhardwaj N, Cockett M, Disis ML, Dranoff G, Gilboa E, Hammond SA, Hershberg R, Korman AJ, Kvistborg P, Melief C, Mellman I, Palucka AK, Redchenko I, Robins H, Sallusto F, Schenkelberg T, Schoenberger S, Sosman J, Türeci Ö, Van den Eynde B, Koff W, Coukos G.

Sci Transl Med. 2016 Apr 13;8(334):334ps9. doi: 10.1126/scitranslmed.aaf0685. Review.

PMID:
27075624
37.

Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials.

Kohrt HE, Tumeh PC, Benson D, Bhardwaj N, Brody J, Formenti S, Fox BA, Galon J, June CH, Kalos M, Kirsch I, Kleen T, Kroemer G, Lanier L, Levy R, Lyerly HK, Maecker H, Marabelle A, Melenhorst J, Miller J, Melero I, Odunsi K, Palucka K, Peoples G, Ribas A, Robins H, Robinson W, Serafini T, Sondel P, Vivier E, Weber J, Wolchok J, Zitvogel L, Disis ML, Cheever MA; Cancer Immunotherapy Trials Network (CITN).

J Immunother Cancer. 2016 Mar 15;4:15. doi: 10.1186/s40425-016-0118-0. eCollection 2016. Review.

38.

Coordinated Activation of Toll-Like Receptor8 (TLR8) and NLRP3 by the TLR8 Agonist, VTX-2337, Ignites Tumoricidal Natural Killer Cell Activity.

Dietsch GN, Lu H, Yang Y, Morishima C, Chow LQ, Disis ML, Hershberg RM.

PLoS One. 2016 Feb 29;11(2):e0148764. doi: 10.1371/journal.pone.0148764. eCollection 2016.

39.

Erratum to: Vaccination with ErbB-2 peptides prevents cancer stem cell expansion and suppresses the development of spontaneous tumors in MMTV-PyMT transgenic mice.

Gil EY, Jo UH, Lee HJ, Kang J, Seo JH, Lee ES, Kim YH, Kim I, Phan-Lai V, Disis ML, Park KH.

Breast Cancer Res Treat. 2016 Feb;155(3):617-8. doi: 10.1007/s10549-016-3715-1. No abstract available.

PMID:
26888722
40.

The Antitumor Efficacy of IL2/IL21-Cultured Polyfunctional Neu-Specific T Cells Is TNFα/IL17 Dependent.

Phan-Lai V, Dang Y, Gad E, Childs J, Disis ML.

Clin Cancer Res. 2016 May 1;22(9):2207-16. doi: 10.1158/1078-0432.CCR-15-2273. Epub 2015 Dec 9.

41.

Underlying Autoimmune Disease Is Not a Contraindication to the Use of Ipilimumab.

Disis ML.

JAMA Oncol. 2016 Feb;2(2):241. doi: 10.1001/jamaoncol.2015.4717. No abstract available.

PMID:
26632762
42.

The Lasker Awards--Recognizing and Highlighting Oncology Research.

Disis ML.

JAMA. 2015 Sep 15;314(11):1123-4. doi: 10.1001/jama.2015.10964. No abstract available.

PMID:
26372574
43.

Epidermal growth factor receptor derived peptide vaccination to prevent lung adenocarcinoma formation: An in vivo study in a murine model of EGFR mutant lung cancer.

Ebben JD, Lubet RA, Gad E, Disis ML, You M.

Mol Carcinog. 2016 Nov;55(11):1517-1525. doi: 10.1002/mc.22405. Epub 2015 Sep 7.

44.

Current methods of epitope identification for cancer vaccine design.

Cherryholmes GA, Stanton SE, Disis ML.

Vaccine. 2015 Dec 16;33(51):7408-7414. doi: 10.1016/j.vaccine.2015.06.116. Epub 2015 Aug 1. Review.

PMID:
26238725
45.

Announcing JAMA Oncology.

Disis ML.

JAMA Oncol. 2015 Apr;1(1):15-6. doi: 10.1001/jamaoncol.2014.239. No abstract available.

PMID:
26182296
46.

Adjuvant Oophorectomy in the Treatment of Early-Stage BRCA Mutation-Positive Breast Cancer.

Disis ML.

JAMA Oncol. 2015 Jun;1(3):313. doi: 10.1001/jamaoncol.2015.0708. No abstract available.

PMID:
26181176
47.

An Autoimmune Response Signature Associated with the Development of Triple-Negative Breast Cancer Reflects Disease Pathogenesis.

Katayama H, Boldt C, Ladd JJ, Johnson MM, Chao T, Capello M, Suo J, Mao J, Manson JE, Prentice R, Esteva F, Wang H, Disis ML, Hanash S.

Cancer Res. 2015 Aug 15;75(16):3246-54. doi: 10.1158/0008-5472.CAN-15-0248. Epub 2015 Jun 18.

48.

Triple-negative breast cancer: immune modulation as the new treatment paradigm.

Disis ML, Stanton SE.

Am Soc Clin Oncol Educ Book. 2015:e25-30. doi: 10.14694/EdBook_AM.2015.35.e25.

49.

Preservation of tumor-host immune interactions with luciferase-tagged imaging in a murine model of ovarian cancer.

Liao JB, Ovenell KJ, Curtis EE, Cecil DL, Koehnlein MR, Rastetter LR, Gad EA, Disis ML.

J Immunother Cancer. 2015 May 19;3:16. doi: 10.1186/s40425-015-0060-6. eCollection 2015.

50.

Th1 epitope selection for clinically effective cancer vaccines.

Disis ML, Watt WC, Cecil DL.

Oncoimmunology. 2014 Dec 13;3(9):e954971. eCollection 2014 Oct.

Supplemental Content

Loading ...
Support Center